NCCN 4th Annual Congress on Hematologic Malignancies

 
 
 

The NCCN 4th Annual Congress on Hematologic Malignancies took place September 11-12, 2009, in New York, New York.

 

Two agents may show promise in CIT

Jen Smith Read Article
Published: 09/30/09

Two second-generation thrombopoetic growth factors have shown promise in the treatment of thrombocytopenia, and an expert postulates the best is yet to come. Romiplostim and eltrombopag have demonstrated unparalleled efficacy in patients with immune thrombocytopenia (ITP), according to David J. Kuter, MD, DPhil, of Harvard Medical School. And he predicts the drugs will fare at least as well in the ongoing studies of patients with chemotherapy-induced thrombocytopenia (CIT). [Read Article]

Prevention key to management of tumor lysis syndrome

Jen Smith Read Article
Published: 09/29/09

Myron Czuczman, MD
Myron Czuczman, MD

Prevention is the single best way to manage tumor lysis syndrome, an expert told the audience at the recent NCCN 4th Annual Congress on Hematologic Malignancies. “Remember one word: prevention,” said Myron S. Czuczman, MD, of Roswell Park Cancer Institute. “If you can prevent it, it’s a lot easier than having to treat it.” [Read Article]

AML management as a paradigm for all cancers

Keely McClain Read Article
Published: 09/28/09

B. Douglas Smith, MD
B. Douglas Smith, MD

ODAC’s recent rejection of 2 new leukemia drugs intended for patients over the age of 60 years has only fueled the need for more clinical trials and better management strategies for the elderly. B. Douglas Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, discussed ways to improve treatment for older patients with acute myeloid leukemia (AML) at the NCCN 4th Annual Congress on Hematologic Malignancies.

  [Read Article]

Speaker favors FCR as frontline choice for CLL

Mark Fuerst Read Article
Published: 09/27/09

The treatment of chronic lymphocytic leukemia (CLL) has improved dramatically in recent times, but questions still remain about whether to treat asymptomatic patients and what is the best front-line regimen for most of them. Susan O’Brien, MD, of the University of Texas M.D. Anderson Cancer Center in Houston, provided some insights on these issues at the NCCN 4th Annual Congress on Hematologic Malignancies held September 11-12 in New York City. [Read Article]

The ins and outs of the new WHO classification

Erilyn Riley Read Article
Published: 09/26/09

Nancy Lee Harris, MD
Nancy Lee Harris, MD

The latest update of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues has been available for about a year. Its first and second printings have sold out, and its third printing has just become available. However, clinicians still find it daunting, confusing, and a real challenge. Nancy Lee Harris, MD, of Harvard Medical School in Boston and an editor of the latest version, highlighted what’s new in the 4th edition and clarified some of the implications for practice. [Read Article]

Novel agents vs transplant in myeloma

Jen Smith Read Article
Published: 09/25/09

George Somlo, MD
George Somlo, MD

Since novel agents first began to demonstrate efficacy in treating multiple myeloma, researchers have wondered whether they might replace the need for tandem transplant in these patients. Two ongoing studies are currently investigating this possibility. George Somlo, MD, FACP, of City of Hope in California, described them in a presentation at the NCCN 4th Annual Congress on Hematologic Malignancies, which took place September 11-12. [Read Article]

Prognostic markers as a Rosetta stone in DLBCL

Mark Fuerst Read Article
Published: 09/24/09

Andrew Zelenetz, MD
Andrew Zelenetz, MD

New prognostic markers in diffuse large B-cell lymphoma (DLBCL) may help clinicians plan treatment and predict outcomes of therapy, said Andrew Zelenetz, MD, of Memorial Sloan-Kettering Cancer Center in New York. “A prognostic marker is a Rosetta stone to providing information across trials,” he said, during his presentation at the NCCN 4th Annual Congress on Hematologic Malignancies held recently in New York City. [Read Article]

Promising new drugs in pipeline for multiple myeloma

Mark Fuerst Read Article
Published: 09/23/09

More than 500 clinical trials are ongoing or about to open in multiple myeloma, with dozens of agents in development, according to Adam Cohen, MD, of Fox Chase Cancer Center in Philadelphia. He discussed the opportunities and challenges that these drugs present at the NCCN 4th Annual Congress on Hematologic Malignancies held recently in New York City. [Read Article]

Presenter describes how to choose drugs for multiple myeloma

Mark Fuerst Read Article
Published: 09/22/09

Seema Singhal, MD
Seema Singhal, MD

A dizzying array of therapeutic agents as first-line or salvage therapy in multiple myeloma (MM) complicates the decision-making process in choosing an appropriate treatment. Seema Singhal, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, clarified what clinicians need to know about available drug combinations, the toxicity of the combinations, and when to use them. She presented her remarks recently at the NCCN 4th Annual Congress on Hematologic malignancies in New York City. [Read Article]

CML as a prototypic stem cell disease

Erilyn Riley Read Article
Published: 09/20/09

Joseph O. Moore, MD
Joseph O. Moore, MD

Although chronic myeloid leukemia (CML) is not a very common disease, it is extraordinarily important in understanding the cancer stem cell. Joseph O. Moore, MD, from the Duke Comprehensive Cancer Center in Durham, North Carolina, discussed the evolution of the cancer stem cell concept using CML as an example, described where we are now and what the future may hold. He delivered his remarks at the NCCN 4th Annual Congress on Hematologic Malignancies held September 11-12 in New York City. [Read Article]

Presenter questions the role of HSCT in MM

Jen Smith Read Article
Published: 09/19/09

Jayesh Mehta, MD
Jayesh Mehta, MD

After more than a decade of research, the medical community still has no definitive conclusions about the role of transplant in multiple myeloma. Some studies suggest single hematopoietic stem cell transplant (HSCT) is the most effective treatment option. Others say tandem HSCT produces superior results. And still others suggest that refraining from transplant altogether is best. Jayesh Mehta, MD, of Northwestern University, reviewed these conflicting results during a panel discussion at the NCCN 4th Annual Congress on Hematologic Malignancies. [Read Article]

Findings may change standard practice for platelet transfusion

Jen Smith Read Article
Published: 09/17/09

David J. Kuter, MD, DPhil
David J. Kuter, MD, DPhil

Research has shown that a majority of platelet donations are used for prophylactic transfusion, but results of 2 new studies may one day change that. One study indicates the standard dose used in prophylactic platelet transfusion can be cut in half and remain effective. The second study goes one step further, suggesting prophylactic transfusion be eliminated completely because patients fare equally as well when they receive platelets prophylactically as when they do not. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}